Magazine Article | February 1, 2019

Combatting Unproven Cell And Gene Therapies Through Regulation And Education

Source: Life Science Leader

By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter

Cell and gene therapies (CGTs), once a dream of science fiction, are now a reality of modern medicine across the developed world. Growing numbers of proven CGTs have gained marketing approval and are available to provide treatments for patients, mostly in life-threatening and rare diseases.

According to the inaugural annual report from the International Society for Cell and Gene Therapy (ISCT), the number of CGTs with marketing authorization increased by 45 percent between 2015 and September 2018. More than a third of the approved therapies are for the treatment of cancer and blood disorders, and over half are based on autologous cells.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader